FRI107 - Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice
| Autor: | Lai, Michelle, Broestl, Jeremy, Juneja, Kavita, Milligan, Scott, Radtchenko, Janna, Younossi, Zobair, Afdhal, Nezam |
|---|---|
| Zdroj: | In Journal of Hepatology August 2020 73 Supplement 1:S452-S452 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect